NRSNNeuroSense Therapeutics Ltd
$0.6901
$0.0031
(0.45%)
Mkt Cap$24.29M
Vol78,525.00
Fundamentals
58
Bullish Sentiment
How do you feel about NRSN?
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS PR Newswire CAMBRIDGE, Mass., June 11, 2026 Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALSExpands...
PR Newswire
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition PR Newswire CAMBRIDGE, Mass., June 9, 2026 Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil...
PR Newswire
NeuroSense Announces Pricing of Insider-Led PIPE Financing
NeuroSense Announces Pricing of Insider-Led PIPE Financing NeuroSense Announces Pricing of Insider-Led PIPE Financing PR Newswire CAMBRIDGE, Mass., April 28, 2026 Financing led by CEO Alon Ben-Noon...
PR Newswire
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
NeuroSense Granted Brazilian Patent Covering PrimeC Composition NeuroSense Granted Brazilian Patent Covering PrimeC Composition PR Newswire CAMBRIDGE, Mass., April 6, 2026 Patent Protection Through...
PR Newswire
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding...
PR Newswire
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update PR Newswire...
PR Newswire
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data...
PR Newswire
PrimeC New Data to Be Presented at AD/PD 2026 Conference
PrimeC New Data to Be Presented at AD/PD 2026 Conference PrimeC New Data to Be Presented at AD/PD 2026 Conference PR Newswire CAMBRIDGE, Mass., March 18, 2026 Dr. Christian Lunetta to Present 'From...
PR Newswire
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity JAMA Neurology Publishes Results from PARADIGM Phase...
PR Newswire
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PR Newswire CAMBRIDGE...
PR Newswire
<
1
2
...
>